Ali Motlagh1, Neda Yaraei2, Ahmad R Mafi3, Farnaz Hosseini Kamal3, Mehdi Yaseri4, Simin Hemati5, Hojatollah Shahbazian6, Abdol-Azim Sedighi7, Reza Khodabakhshi8, Ali Taghizadeh9, Jamshid Ansari10, Farshad Seyednejad11, Reza Khanduzi12, Khosro Mojir Sheibani3, Payam Azadeh3, Mohamad Hasan Emranpour13, Ahmad Mosalei14, Soheil Vojdani10, Ali Mohamad Nazari15, Leila Nazarimenesh16, Abdolah Fazl-Alizadeh17, Mohamad Esmaeil Akbari18. 1. 1)Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2)Radiation Oncology Department, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.18)National Program Director, Center for NON-COMMUNICABLE Disease, Deputy of Health, Ministry of Health and Medical Education, Tehran, Iran. agmotlagh@yahoo.com. 2. Sepas Organization, Tehran, Iran. 3. Radiation Oncology Department, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran. 5. Radiation Oncology Department, Seyed-ol-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Radiation Oncology Department, Golestan Hospital, Ahvaz University of Medical Sciences, Ahvaz, Iran. 7. Mahdiye Oncology Center, Hamedan, Iran. 8. Radiation Oncology Department, Fayazbakhsh Hospital, Tehran, Iran. 9. Radiation Oncology Department, Omid Hospital, Mashad University of Medical Sciences, Mashad, Iran. 10. Radiation Oncology Department, Khansari Hospital, Arak, Iran. 11. Radiation Oncology Department, Imam Khomeini Hospital, Tabriz, Iran. 12. Radiation Oncology Department, Shafa Hospital, Gorgan, Iran. 13. Shahid Rajaei Oncology Center, Babolsar, Iran. 14. Radiation Oncology Department, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. 15. Tarbiat Moalem University, Tehran, Iran. 16. Jahad Daneshgahi, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 17. Iranian Cancer Society, Tehran, Iran. 18. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVES: There is still contradictory evidence on disclosure preferences regarding cancer diagnosis. The aim of this study was to evaluate the preference of cancer patients for knowing the truth about their disease, as well as the factors that might have an impact on these preferences. METHOD: This study was conducted in 11 cancer centers in Iran. A questionnaire was used to collect data, and all patients above 15 years of age who were willing to participate were included in the study. The patients were asked if they were aware of the malignant nature of their disease, and if they came to know about their disease at the time of initial diagnosis, or later. The patients were then asked about the way they looked upon their disease. In the final part of the questionnaire, the participants were asked the level of involvement they prefer to have in making treatment decisions. RESULTS: In total, 1226 patients were enrolled in this study, only 565 (46.7%) of whom were aware of their disease at the time of diagnosis, and 878 (72.7%) at the time of interview, while 980 (85.2%) were willing to receive information about their disease. Patients' awareness was significantly associated with age under 50 years, female gender, having breast, skin or head and neck cancer, and having medical care in Shiraz or Hamadan while it was not associated with the stage or accompanying illness. CONCLUSION: While the majority of Iranian cancer patients prefer to be aware of the nature of their disease and have an active role in treatment decision making, they do not receive this information.
OBJECTIVES: There is still contradictory evidence on disclosure preferences regarding cancer diagnosis. The aim of this study was to evaluate the preference of cancerpatients for knowing the truth about their disease, as well as the factors that might have an impact on these preferences. METHOD: This study was conducted in 11 cancer centers in Iran. A questionnaire was used to collect data, and all patients above 15 years of age who were willing to participate were included in the study. The patients were asked if they were aware of the malignant nature of their disease, and if they came to know about their disease at the time of initial diagnosis, or later. The patients were then asked about the way they looked upon their disease. In the final part of the questionnaire, the participants were asked the level of involvement they prefer to have in making treatment decisions. RESULTS: In total, 1226 patients were enrolled in this study, only 565 (46.7%) of whom were aware of their disease at the time of diagnosis, and 878 (72.7%) at the time of interview, while 980 (85.2%) were willing to receive information about their disease. Patients' awareness was significantly associated with age under 50 years, female gender, having breast, skin or head and neck cancer, and having medical care in Shiraz or Hamadan while it was not associated with the stage or accompanying illness. CONCLUSION: While the majority of Iranian cancerpatients prefer to be aware of the nature of their disease and have an active role in treatment decision making, they do not receive this information.
Authors: Diego de Araujo Toloi; Gabriela Critchi; Andrea Mangabeira; Felipe Matsushita; Rachel P Riechelmann; Paulo M Hoff; Everardo D Saad Journal: Ecancermedicalscience Date: 2015-09-22
Authors: Mojgan Ansari; Maryam Rassouli; Mohamad Esmaiel Akbari; Abbas Abbaszadeh; Ali Akbari Sari Journal: Int J Community Based Nurs Midwifery Date: 2018-04